Investor's Business Daily on MSN1h
IBD Stock Of The Day: Meta Forms New Base Amid AI Spending Debate
Meta Platforms is the IBD Stock of the Day for Monday. Shares of the Facebook parent company have formed a flat base pattern after bouncing back last week from a slight earnings letdown.Please watch ...
Investor's Business Daily on MSN3h
IBD Rating Upgrades: Chesapeake Utilities Flashes Improved Relative Price Strength
A Relative Strength Rating upgrade for Chesapeake Utilities shows improving technical performance. Will it continue?
Medscape6h
Does Bezlotoxumab Boost FMT Efficacy in IBD Patients With Recurrent CDI?
A randomized controlled trial finds no clear benefit of adding bezlotoxumab to FMT in patients with IBD and recurrent C difficile infection.
Spyre Therapeutics Advances IBD Treatment Pipeline
Aeglea Biotherapeutics Inc. ( (SYRE) ) has released its Q3 earnings. Here is a breakdown of the information Aeglea Biotherapeutics Inc.